Pharsight

Levulan patents expiration

LEVULAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11571478 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US11077192 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US10357567 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US11135293 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US11690914 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

Levulan is owned by Dusa.

Levulan contains Aminolevulinic Acid Hydrochloride.

Levulan has a total of 5 drug patents out of which 0 drug patents have expired.

Levulan was authorised for market use on 03 December, 1999.

Levulan is available in solution;topical dosage forms.

Levulan can be used as treatment of actinic keratoses of upper extremities by photodynamic therapy.

The generics of Levulan are possible to be released after 12 January, 2038.

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 03 December, 1999

Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION;TOPICAL

More Information on Dosage

LEVULAN family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic